Two cases of refractory Wegener's granulomatosis successfully treated with rituximab

被引：58

作者：

Tamura, Naoto ^{[1
]}

Matsudaira, Ran ^{[1
]}

Hirashima, Mika ^{[1
]}

Ikeda, Makoto ^{[1
]}

Tajima, Michiko ^{[1
]}

Nawata, Masuyuki ^{[1
]}

Morimoto, Shinji ^{[1
]}

Kaneda, Kazuhiko ^{[1
]}

Kobayashi, Shigeto

Hashimoto, Hiroshi

Takasaki, Yoshinari ^{[1
]}

机构：

[1] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Tokyo 113, Japan

来源：

INTERNAL MEDICINE | 2007年 / 46卷 / 07期

关键词：

Wegener's granulomatosis; anti-neutrophil cytoplasmic antibody (ANCA); rituximab; therapy; capture ELISA;

D O I：

10.2169/internalmedicine.46.6156

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Conventional therapy for Wegener's granulomatosis, steroid and cyclophosphamide, fails to control disease activity in some refractory patients and has treatment-related toxicity. B cell depletion therapy using rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for certain autoimmune diseases including antineutrophil cytoplasmic antibody ( ANCA) - associated systemic vasculitis. We report two refractory cases of Wegener's granulomatosis: one with bronchial and pulmonary involvement and retroorbital granuloma, the other with retroorbital granuloma and hypertrophic pachymeningitis causing severe headache. Rituximab was effective in both cases, with diminished granuloma and reduced ANCA titers, allowing steroids to be tapered. No adverse effects were detected.

引用

页码：409 / 414

页数：6

共 24 条

[1] Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations [J].

Aries, P. M. ;

Hellmich, B. ;

Voswinkel, J. ;

Both, M. ;

Noelle, B. ;

Holl-Ulrich, K. ;

Lamprecht, P. ;

Gross, W. L. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) :853-858

[2] The spectrum of Wegener's granulomatosis and disease relapse [J].

Bacon, PA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (04) :330-332

[3]

Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO

[4]

2-O

[5] Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study [J].

Booth, AD ;

Almond, MK ;

Burns, A ;

Ellis, P ;

Gaskin, G ;

Neild, GH ;

Plaisance, M ;

Pusey, CD ;

Jayne, DRW .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :776-784

[6] Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor α agents:: an open-label observational study [J].

Brulhart, L. ;

Ciurea, A. ;

Finckh, A. ;

Notter, A. ;

Waldburger, J. M. ;

Kyburz, D. ;

Gabay, C. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) :1255-1257

[7]

de Groot K, 2005, KIDNEY BLOOD PRESS R, V28, P195

[8] Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis [J].

de Groot, K ;

Rasmussen, N ;

Bacon, PA ;

Tervaert, JWC ;

Feighery, C ;

Gregorini, G ;

Gross, WL ;

Luqmani, R ;

Jayne, DRW .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2461-2469

[9] The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review [J].

de Groot, K ;

Adu, D ;

Savage, COS .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (10) :2018-2027

[10] The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial [J].

Emery, P ;

Fleischmann, R ;

Filipowicz-Sosnowska, A ;

Schechtman, J ;

Szczepanski, L ;

Kavanaugh, A ;

Racewicz, AJ ;

Van Vollenhoven, RF ;

Li, NF ;

Agarwal, S ;

Hessey, EW ;

Shaw, TM .

ARTHRITIS AND RHEUMATISM, 2006, 54 (05) :1390-1400

← 1 2 3 →